| Name | Title | Contact Details |
|---|
Alliance HealthCard, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
In 2016, OmniGuide Surgical and Domain Surgical were merged, creating an organization focused on providing better outcomes and a safer, more seamless surgical experience. Today, OmniGuide Surgical`s Enhanced Safety Flexible CO2 Laser Fibers and Domain Surgical`s FMX Ferromagnetic Technology are used in the most challenging surgical procedures throughout the world, safely delivering energy resulting in the preservation of healthy tissue. OmniGuide Surgical, based in Lexington, MA, USA, is the leader in flexible fiber CO2 laser technology; providing products that enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, located in Salt Lake City, UT, USA, provides a patented ferromagnetic technology designed to provide safety and predictability in select surgical procedures that require cutting, coagulating and sealing tissue.
Stockamp delivers: Stockamp helps high-performing hospitals reach the pinnacle of financial and operational excellence. We invented and perfected the science of revenue cycle management for hospitals and health systems, based on our unmatched
Calhoun Senior Living is a Anderson, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.